Mutation Analysis of BRAF, MEK1 and MEK2 in 15 Ovarian Cancer Cell Lines: Implications for Therapy
2007

Mutation Analysis of BRAF, MEK1 and MEK2 in Ovarian Cancer Cell Lines

Sample size: 15 publication Evidence: moderate

Author Information

Author(s): Estep Anne L., Palmer Chana, McCormick Frank, Rauen Katherine A.

Primary Institution: University of California at San Francisco

Hypothesis

BRAF and MEK1/2 mutations may be more common than previously recognized in ovarian cancer.

Conclusion

The study identifies novel BRAF mutations and the first MEK1 mutation associated with human cancer, suggesting implications for treatment.

Supporting Evidence

  • BRAF mutations were identified in four of the fifteen ovarian cancer cell lines studied.
  • Two novel BRAF mutations were found, along with the first mutation in MEK1 associated with human cancer.
  • Functional data indicate that the MEK1 mutation may alter activation through the MAPK pathway.

Takeaway

Scientists looked at 15 ovarian cancer cell lines to find mutations in certain genes, and they found some new mutations that could help doctors treat the cancer better.

Methodology

Fifteen ovarian cancer cell lines were screened for mutations using bidirectional direct sequencing in all coding regions of BRAF, MEK1, and MEK2.

Limitations

The study only analyzed 15 cell lines, which may not represent all ovarian cancer cases.

Participant Demographics

The study involved ovarian cancer cell lines, not human participants.

Digital Object Identifier (DOI)

10.1371/journal.pone.0001279

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication